Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic789 active trials18 approved drugs279 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Clinical trials
2,962 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (534)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02770820 | Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 9 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 29, 2021 | clinicaltrials |
| NCT04051996 | GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia | terminated | Phase 2 | 1 | Yale UniversityOTHER | 1 | Oct 15, 2021 |
| NCT02229266 | Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML(HINKL) | terminated | Phase 2 | 1 | Technische Universität DresdenOTHER | 1 | Aug 16, 2021 | clinicaltrials |
| NCT01113502 | Eltrombopag in Elderly Acute Myelogenous Leukemia (AML) | terminated | Phase 1 / Phase 2 | 44 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT02440568 | AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients | terminated | Phase 1 / Phase 2 | 22 | University of Illinois at ChicagoOTHER | 1 | Jul 6, 2021 | clinicaltrials |
| NCT01486784 | A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 27 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 24, 2021 | clinicaltrials |
| NCT03113071 | Safety and Activity of Digoxin With Decitabine in Adult AML and MDS | terminated | Phase 1 / Phase 2 | 1 | Fox Chase Cancer CenterOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT00615784 | Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia(UPCC04407) | terminated | Phase 2 | 24 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT03709576 | Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML | terminated | Phase 2 | 3 | Milton S. Hershey Medical CenterOTHER | 1 | Dec 16, 2020 | clinicaltrials |
| NCT01656252 | Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission(PrE0901) | terminated | Phase 1 / Phase 2 | 15 | PrECOG, LLC.OTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT02953561 | Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT02991898 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | terminated | Phase 2 | 3 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 29, 2020 | clinicaltrials |
| NCT03718143 | AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis | terminated | Phase 2 | 6 | NYU Langone HealthOTHER | 1 | Jun 2, 2020 | clinicaltrials |
| NCT03071276 | Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia | terminated | Phase 2 | 37 | St. Jude Children's Research HospitalOTHER | 1 | May 22, 2020 | clinicaltrials |
| NCT02038153 | Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 3 | Albert Einstein College of MedicineOTHER | 1 | May 14, 2020 | clinicaltrials |
| NCT02349178 | Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT | terminated | Phase 2 | 6 | Medical College of WisconsinOTHER | 1 | Mar 9, 2020 | clinicaltrials |
| NCT02341495 | Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65(EXJADE) | terminated | Phase 2 | 4 | Elizabeth HenryOTHER | 1 | Feb 27, 2020 | clinicaltrials |
| NCT00939653 | T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML) | terminated | Phase 2 | 6 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Feb 19, 2020 | clinicaltrials |
| NCT00539656 | Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers(Cord Blood) | terminated | Phase 1 / Phase 2 | 3 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 18, 2020 | clinicaltrials |
| NCT02343939 | Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)(ENTO in AML) | terminated | Phase 1 / Phase 2 | 148 | Gilead SciencesINDUSTRY | 3 | Nov 15, 2019 | clinicaltrials |
| NCT03195010 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia | terminated | Phase 2 | 4 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT01873495 | Omacetaxine for Consolidation and Maintenance | terminated | Phase 2 | 7 | Emory UniversityOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT02399917 | Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia | terminated | Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT01289678 | Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia | terminated | Phase 2 | 18 | Leo W. Jenkins Cancer CenterOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT00276159 | Study of Immune Response Modifier in the Treatment of Hematologic Malignancies | terminated | Phase 2 | 6 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT01160354 | Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML) | terminated | Phase 1 / Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT02337478 | Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 2 | 5 | Wake Forest University Health SciencesOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT02634827 | Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation | terminated | Phase 2 | 1 | Mayo ClinicOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT00167180 | Post Transplant Donor Lymphocyte Infusion | terminated | Phase 2 | 57 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT02477787 | Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDS(DNKI-4) | terminated | Phase 2 | 77 | Asan Medical CenterOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2019 | clinicaltrials |
| NCT01853228 | A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 17 | Janssen Research & Development, LLCINDUSTRY | 7 | Jun 17, 2019 | clinicaltrials |
| NCT00808080 | A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell (AHSC) Transplantation for Acute Myeloid Leukemia (AML)(AMLCTL) | terminated | Phase 1 / Phase 2 | 6 | Thomas A. Lane, MDOTHER | 1 | Apr 9, 2019 | clinicaltrials |
| NCT02030405 | Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 2 | 4 | Steven E. CoutreOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT03381118 | Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients | terminated | Phase 2 | 16 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT02418000 | A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations | terminated | Phase 1 / Phase 2 | 27 | Spirita Oncology, LLCINDUSTRY | 1 | Mar 20, 2019 | clinicaltrials |
| NCT00655395 | Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine | terminated | Phase 1 / Phase 2 | 25 | Viron Therapeutics IncINDUSTRY | 1 | Jan 28, 2019 | clinicaltrials |
| NCT02614560 | A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients | terminated | Phase 1 / Phase 2 | 14 | Seagen Inc.INDUSTRY | 1 | Jan 9, 2019 | clinicaltrials |
| NCT00043810 | Study of Gelonin Purging of Autologous Stem Cells for Transplantation | terminated | Phase 1 / Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT02992860 | Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY(SAMBA) | terminated | Phase 2 | 25 | GWT-TUD GmbHOTHER | 2 | Oct 25, 2018 | clinicaltrials |
| NCT01846624 | Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | terminated | Phase 2 | 13 | David IberriOTHER | 1 | Sep 27, 2018 | clinicaltrials |
| NCT01588951 | Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior | terminated | Phase 2 / Phase 3 | 10 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 14, 2018 | clinicaltrials |
| NCT02351037 | Study of Ibrutinib in Subjects With Acute Myeloid Leukemia | terminated | Phase 2 | 36 | Pharmacyclics LLC.INDUSTRY | 1 | Aug 14, 2018 | clinicaltrials |
| NCT01795924 | Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome(AML/MDS) | terminated | Phase 1 / Phase 2 | 13 | Biosuccess Biotech Co., Ltd.INDUSTRY | 1 | Jul 24, 2018 | clinicaltrials |
| NCT01745913 | Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies | terminated | Phase 2 | 2 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 11, 2018 | clinicaltrials |
| NCT01050764 | Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | terminated | Phase 1 / Phase 2 | 10 | Everett MeyerOTHER | 1 | Jun 27, 2018 | clinicaltrials |
| NCT02532010 | Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML(Pacritinib) | terminated | Phase 2 | 13 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 15, 2018 | clinicaltrials |
| NCT00593554 | Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies | terminated | Phase 2 | 9 | Sherif S. FaragOTHER | 1 | Apr 10, 2018 | clinicaltrials |
| NCT01907815 | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia | terminated | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Apr 6, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Oct 29, 2021source: clinicaltrials